Physician profile
Cevher Ozcan
NPI 1760636146
$1,686.89
in general payments reported to CMS, 2019-2025
11 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2021: $171 · 2022: $24.38 · 2023: $448 · 2024: $470 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $537.22 | 2022-2025 | Cobalt Dr Mri Surescan, Selectsecure, Micra |
| Boston Scientific Corporation | $390.72 | 2019-2025 | Accolade Sr |
| Abbott Laboratories | $239.35 | 2023-2025 | Aveir |
| Cvrx, INC. | $171.33 | 2021 | |
| Philips North America LLC | $124.55 | 2024 | (9520) Igt Devices Undivided |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.73 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $39.19 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $32.42 | 2019 | |
| Amgen INC. | $24.02 | 2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $13.86 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cevher Ozcan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.